Several trials in MS patients using intradermal or intramuscular injections of synthetic TCR Vβ5.2 and/or and Vβ6.1 peptides reported clinical improvements and reduced frequency of MBP-specific T cells and the induction of TCR peptide-specific T cells (48–50). Here, MBP is linked to myeloid sarcoma.